Lazard Asset Management
AKBA icon

Lazard Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Lazard Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94,563
Closed -$152K – 1862
2025
Q4 		$152K Buy
94,563
+69,389
+276% +$145K ﹤0.01% 1688
2025
Q3 		$68.7K Sell
25,174
-91,311
-78% -$304K ﹤0.01% 1723
2025
Q2 		$424K Buy
+116,485
New +$320K ﹤0.01% 1540
2024
Q2 		– Sell
-43,545
Closed -$79K – 2212
2024
Q1 		$79K Buy
+43,545
New +$69.6K ﹤0.01% 1605
2020
Q3 		– Sell
-5,972
Closed -$81K – 1598
2020
Q2 		$81K Buy
+5,972
New +$61.8K ﹤0.01% 1068
2019
Q4 		– Sell
-2,645
Closed -$10K – 1519
2019
Q3 		$10K Buy
+2,645
New +$11.3K ﹤0.01% 1302

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Lazard Asset Management's AKBA Position: Q1 2026 in Review

Lazard Asset Management sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 94,563 shares — an estimated $152K sold.

Lazard Asset Management first reported a position in AKBA in Q3 2019 and held it in 6 quarters. The position peaked at $424K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Lazard Asset Management reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 94,563 Akebia Therapeutics shares in Q1 2026, an estimated $152K.
  • Lazard Asset Management first reported a position in Akebia Therapeutics in Q3 2019 and held it in 6 quarters.
  • Lazard Asset Management's Akebia Therapeutics position peaked at $424K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.